Biotechnology

Tuesday May 19, 2026 - 1:47 pm

InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech with AI-Enhanced Robotics Strategy

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments,” reads a recent article. “At the core of this pivot is…

Friday May 15, 2026 - 11:50 am

InvestorNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at Intersection of Precision Medicine, Preventive Care

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision medicine company leveraging epigenetics, genetics and artificial intelligence, is poised to meet demands as cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide. “Cardio Diagnostics is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized cardiovascular insights from a simple blood…

Wednesday May 06, 2026 - 1:08 pm

InvestorNewsBreaks – AI Meets Multi-Omics: Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Earlier, More Precise Cardiac Insights

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. “Cardio Diagnostics Holdings is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (‘AI’) and multi-omic biomarkers to deliver actionable…

Thursday Apr 30, 2026 - 1:49 pm

InvestorNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Precision Cardiology with Multi-Omic AI Platform

Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. The company is “developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample,” reads a recent article.…

Wednesday Apr 29, 2026 - 2:00 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Leveraging Vertical Integration to Target Precision Medicine Market

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its efforts to build vertical integration across telemedicine, pharmaceuticals, and clinical services. “At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific patient needs. This segment aims to tackle the growing gap in traditional pharmaceutical manufacturing… Through operating licensed compounding facilities, the company is strategically…

Friday Apr 24, 2026 - 2:48 pm

InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. “By focusing on improving the therapeutic index of existing…

Friday Apr 24, 2026 - 2:16 pm

InvestorNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advances Toward Commercial Deployment of AI Solution

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent article that discussed its move toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector. The publication reads, “The biotechnology company…

Friday Apr 24, 2026 - 1:47 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Aligns with Next Phase of Telehealth Through Integrated Platform

Earth Science Tech (OTC: ETST) is positioned for opportunity as telehealth evolves from simple video visits into a comprehensive care model. “The company describes itself as a strategic holding company that acquires and actively manages operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and selected consumer markets. ETST’s healthcare-related holdings include telemedicine and pharmaceutical operations designed to support a more connected platform approach; in…

Thursday Apr 23, 2026 - 12:22 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Collaborates to Advance Next-Gen ECG Solutions

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology. The publication indicates that the move, “highlights HeartBeam’s growing focus on artificial intelligence (‘AI’)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions. The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai…

Friday Apr 17, 2026 - 1:13 pm

InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression…

Friday Apr 17, 2026 - 12:29 pm

InvestorNewsBreaks – Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of its strategy is the integration of epigenetics, genetics,…

Wednesday Apr 15, 2026 - 12:04 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Advancing Multi-Platform Healthcare Strategy

Earth Science Tech (OTC: ETST), a strategic holding company, was featured in a recent article that discussed its strives to build value by acquiring and actively managing businesses. The publication reads, “Earth Science Tech takes an approach that prioritizes capital discipline, execution, and long-term value creation across the platforms it operates, while focusing on scaling businesses that can grow sustainably and increase shareholder value. The wholly…

Tuesday Apr 14, 2026 - 1:18 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development

Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. “Soligenix exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact,” the publication reads. “Platform-based…

Thursday Feb 19, 2026 - 2:46 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Showcased for Advancing Innovative ECG Platform

HeartBeam (NASDAQ: BEAT) was featured among a select group of medical device companies in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. An article discussing this reads, “The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity ECG platform designed to capture the heart’s…

Wednesday Feb 11, 2026 - 2:46 pm

InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. “Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications,” reads a recent article. “At the center of LIXTE’s strategy is protein phosphatase…

Friday Feb 06, 2026 - 2:39 pm

InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target,” reads a recent article. “LIXTE’s platform is built on its proprietary LB-100 compound,…

Friday Feb 06, 2026 - 1:55 pm

InvestorNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach

Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed the company’s release of positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. “Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited…

Friday Jan 23, 2026 - 3:15 pm

InvestorNewsBreaks – RiVax(R) Positions Soligenix Inc. (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts

Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, was featured in a recent article discussing its development of a vaccine candidate known as RiVax(R) to protect against ricin exposure. These efforts position the company at the center of biodefense preparedness as public awareness of ricin’s lethality grows. “In a counter-terrorism operation in India, authorities recently foiled a ricin plot, underscoring how easily accessible…

Friday Jan 09, 2026 - 12:44 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM). The study focuses on the treatment of cutaneous T-cell lymphoma, with the…

Friday Jan 09, 2026 - 12:11 pm

InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus

Oncotelic Therapeutics (OTCQB: OTLC) is positioned at the heart of the evolving landscape of pharmaceutical innovation, applying ultra-small carrier technologies to elevate existing cancer therapies. “The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds,” reads a recent article. “The advantages of nanoparticle delivery in pharma are significant… The contemporary view holds that nanocarrier-enabled formulations may be as…

Wednesday Dec 17, 2025 - 2:21 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. “The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of…

Thursday Dec 04, 2025 - 1:37 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) was featured in a BioMedWire Podcast discussing its sharpened focus on glioblastoma multiforme (“GBM”), one of the deadliest and least treatable forms of cancer. In the interview, CEO John Climaco said of GBM, “Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.” An article discussing this reads, “The…

Friday Nov 28, 2025 - 2:14 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above…

Friday Nov 07, 2025 - 3:14 pm

InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee (“HREC”) to begin enrolling patients in clinical trials for Sapu003, an injectible form of Afinitor(R) (everolimus) for breast cancer treatment. Using Sapu Nano’s proprietary Deciparticle(TM) technology, Sapu003 delivers Everolimus directly into the bloodstream. “The approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug…

Thursday Nov 06, 2025 - 3:44 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Eyes Dermatology Market with SGX302’s Encouraging Early Results

Soligenix (NASDAQ: SNGX) is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis, building on promising phase 1/2 data. Early results from the trial show encouraging signs of safety and biological activity, highlighting SGX302’s potential as a novel, well-tolerated treatment for a chronic autoimmune skin condition affecting millions globally. Leveraging its experience with hypericin-based therapies, Soligenix aims to address…

Friday Oct 24, 2025 - 3:26 pm

InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market

NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that discussed its approach to bring preservative-free ketamine-based therapies to market, pursuing distinct regulatory and commercial pathways for both KETAFREE(TM) and NRX-100. “The company recently refiled an Abbreviated New Drug Application (‘ANDA’) for KETAFREE(TM), a preservative-free intravenous (‘IV’) ketamine formulation intended for all currently approved ketamine indications,” the article reads. “This filing follows the U.S.…

Friday Oct 17, 2025 - 2:46 pm

InvestorNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Unveils IzoView: A Game-Changing Platform for Next-Gen Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is leading a transformation in breast cancer screening with its flagship IzoView Breast CT Imaging System, a next-generation technology designed to overcome the long-standing limitations of traditional mammography. Unlike compression-based 2D imaging, IzoView delivers true 360-degree, 3D visualization without discomfort, enabling clearer detection—especially in dense breast tissue, which often obscures lesions in standard scans. With a rapid 10-second…

Friday Oct 17, 2025 - 2:12 pm

InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and…

Thursday Oct 16, 2025 - 2:16 pm

InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, recently secured approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine. “The ruling allows the company to re-file its Abbreviated New Drug Application (‘ANDA’) for the product, which it has now done, a key step in bringing it to market,” reads a recent article. “Currently,…

Thursday Oct 16, 2025 - 1:22 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its development of a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. “The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems… The VALID-ECG study results carry significant…

Tuesday Oct 14, 2025 - 3:34 pm

InvestorNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment

Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a recent article that discussed its preparation for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026. This comes “in the wake of its optimistic…

Wednesday Oct 08, 2025 - 3:19 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) on the Beat of Cardiac Innovation

HeartBeam (NASDAQ: BEAT) is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. A recent article discussing this reads, “HeartBeam plans to initiate commercialization immediately upon receiving FDA clearance. The company’s vision is to empower patients and healthcare providers by offering a portable, cable-free ECG solution that combines clinical-grade accuracy with ease of use. This innovation is poised to reduce the burden…

Wednesday Oct 08, 2025 - 2:24 pm

InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has re-filed an Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free intravenous (“IV”) ketamine formulation intended for all currently approved ketamine indications. This follows FDA approval of NRx’s Suitability Petition… KETAFREE(TM) is designed to eliminate benzethonium chloride (“BZT”), a known neurotoxic and cytotoxic preservative still present in many ketamine formulations. NRx previously submitted a Citizen Petition…

Friday Sep 26, 2025 - 2:04 pm

InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) ECG System Offers Real-Time Cardiac Insights

HeartBeam (NASDAQ: BEAT) is positioned amid limitations of traditional 12-lead electrocardiogram (“ECG”) systems, often including cumbersome setups and restricted accessibility. The company “is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims…

Wednesday Sep 24, 2025 - 3:41 pm

InvestorNewsBreaks – Solving the Value-Based Care Puzzle: Adageis Brings Clarity with AI

Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. “By focusing on simplicity, contract visibility, and measurable financial outcomes, the firm aims to address one of the most pressing challenges in U.S. healthcare: how to reward high-quality care with appropriate compensation,” reads a…

Friday Sep 19, 2025 - 1:11 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Eyes Clear Development Pathway for AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB) is a transdermal pharmaceutical developer that has secured crucial FDA engagement for its lead abuse-deterrent technology. “Nutriband’s FDA Type C Meeting approval for AVERSA(TM) Fentanyl signals agency recognition of the product’s potential to address critical unmet medical needs. The Sept. 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine focuses on Chemistry, Manufacturing, and Controls (‘CMC’) plans spanning the…

Tuesday Sep 09, 2025 - 3:48 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Scales Manufacturing, Eyes Global Commercialization of AVERSA(TM)

Nutriband (NASDAQ: NTRB) was featured in a recent publication that discussed the company’s milestones, innovative platform, and lead product, AVERSA(TM) Fentanyl. NTRB’s technology “incorporates aversive agents into fentanyl patches to prevent misuse and accidental exposure. The company has built a global IP protection strategy, securing patents across the United States, Europe, Asia and Australia. With commercialization manufacturing scaled up in collaboration with Kindeva, Nutriband is…

Tuesday Sep 09, 2025 - 2:26 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently released second quarter 2025 financial results and provided an update on clinical programs. “The company emphasized progress toward an NDA submission for its lead asset CNM-Au8® in ALS, expected in the fourth quarter of 2025,”…

Friday Aug 29, 2025 - 2:56 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro Pipeline

Clene (NASDAQ: CLNN), together with its wholly owned subsidiary, Clene Nanomedicine Inc., is advancing its lead candidate CNM-Au8®, a unique and needed oral treatment for amyotrophic lateral sclerosis (“ALS”), toward a potential FDA accelerated approval. “Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months could be major valuation catalysts for investors… Clene is preparing to…

Tuesday Aug 26, 2025 - 3:39 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Paves Way to Redefine Cardiac Care

HeartBeam (NASDAQ: BEAT) has secured foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system. “The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings,” reads a recent article. “With the clearance secured, HeartBeam plans to expand access…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions